Ocular Therapeutix logo

Ocular TherapeutixNASDAQ: OCUL

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

25 July 2014

Next earnings report:

07 November 2024

Last dividends:

N/A

Next dividends:

N/A
$1.63 B
-11%vs. 3y high
78%vs. sector
-vs. 3y high
-vs. sector
-96%vs. 3y high
79%vs. sector
-11%vs. 3y high
87%vs. sector

Price

after hours | Fri, 01 Nov 2024 20:15:53 GMT
$10.45-$0.08(-0.76%)

Dividend

No data over the past 3 years
$16.44 M$17.14 M
$16.44 M-$43.78 M

Analysts recommendations

Institutional Ownership

OCUL Latest News

Ocular Therapeutix (OCUL) Moves 6.1% Higher: Will This Strength Last?
zacks.com14 October 2024 Sentiment: NEUTRAL

Ocular Therapeutix (OCUL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Ocular Therapeutix™ to Present at October Ophthalmology Meetings
globenewswire.com09 October 2024 Sentiment: POSITIVE

BEDFORD, Mass., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions, today announced participation in multiple panels and presentations across three ophthalmology meetings in Chicago, Illinois during October 2024.

Ocular Therapeutix™ to Present at September Retina Meetings
globenewswire.com05 September 2024 Sentiment: POSITIVE

BEDFORD, Mass., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions, today announced multiple presentations across four retina meetings being held in Portugal and Spain in September 2024.

Ocular Therapeutix™ to Present at Two Investor Conferences in September
globenewswire.com04 September 2024 Sentiment: POSITIVE

BEDFORD, Mass., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions, today announced that it will participate in two investor conferences in September:

Wall Street Analysts See an 85.43% Upside in Ocular Therapeutix (OCUL): Can the Stock Really Move This High?
zacks.com09 August 2024 Sentiment: POSITIVE

The consensus price target hints at an 85.4% upside potential for Ocular Therapeutix (OCUL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Ocular Therapeutix, Inc. (OCUL) Q2 2024 Earnings Call Transcript
seekingalpha.com09 August 2024 Sentiment: NEUTRAL

Ocular Therapeutix, Inc. (NASDAQ:OCUL ) Q2 2024 Earnings Conference Call August 7, 2024 8:00 AM ET Company Participants Bill Slattery - VP, IR Pravin Dugel - Executive Chairman, President, CEO Conference Call Participants Tazeen Ahmad - Bank of America Merrill Lynch Biren Amin - Piper Sandler Tara Bancroft - TD Cowen Colleen Kusy - Baird Kelly Shi - Jefferies Sean McCutcheon - Raymond James Yi Chen - H.C. Wainwright & Co. Operator Good morning, and welcome to the Ocular Therapeutix second-quarter 2024 earnings conference call.

Ocular Therapeutix: Betting On Axpaxli For A Major Market Breakthrough
seekingalpha.com03 June 2024 Sentiment: POSITIVE

Ocular Therapeutix is a biopharmaceutical company with a successful commercial product, Dextenza, generating $57.9 million in revenue in 2023. The company's main value driver is Axpaxli, an axitinib intravitreal implant in phase 3 trials for wet age-related macular degeneration (wet AMD). The company has a strong financial position with $482.9 million in cash and a 3.5-year cash runway, minimizing dilution risk.

Ocular Therapeutix™ To Present at Two Ophthalmology Meetings, May 4-9, 2024
GlobeNewsWire03 May 2024 Sentiment: NEGATIVE

The 2024 OIS Retina and ARVO conferences are taking place in Seattle, Washington.

Down -17.88% in 4 Weeks, Here's Why Ocular Therapeutix (OCUL) Looks Ripe for a Turnaround
Zacks Investment Research09 April 2024 Sentiment: POSITIVE

Ocular Therapeutix (OCUL) is now considered oversold from a technical standpoint, suggesting that the intense selling pressure on the stock may be easing. Additionally, with Wall Street analysts largely raising their earnings estimates, there is a possibility of a turnaround in the stock's performance in the short term.

Ocular Therapeutix™ To Present Data at the 2024 ASCRS Annual Meeting (American Society of Cataract and Refractive Surgery)
GlobeNewsWire26 March 2024 Sentiment: POSITIVE

BEDFORD, Mass., March 26, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to enhancing people's vision and quality of life through the development and commercialization of innovative therapies for wet age-related macular degeneration (wet AMD), diabetic retinopathy, and other diseases and conditions of the eye, announced multiple scientific presentations at the 2024 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting being held April 5-8 in Boston, Massachusetts.

  • 1(current)

What type of business is Ocular Therapeutix?

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.

What sector is Ocular Therapeutix in?

Ocular Therapeutix is in the Healthcare sector

What industry is Ocular Therapeutix in?

Ocular Therapeutix is in the Biotechnology industry

What country is Ocular Therapeutix from?

Ocular Therapeutix is headquartered in United States

When did Ocular Therapeutix go public?

Ocular Therapeutix initial public offering (IPO) was on 25 July 2014

What is Ocular Therapeutix website?

https://www.ocutx.com

Is Ocular Therapeutix in the S&P 500?

No, Ocular Therapeutix is not included in the S&P 500 index

Is Ocular Therapeutix in the NASDAQ 100?

No, Ocular Therapeutix is not included in the NASDAQ 100 index

Is Ocular Therapeutix in the Dow Jones?

No, Ocular Therapeutix is not included in the Dow Jones index

When was Ocular Therapeutix the previous earnings report?

No data

When does Ocular Therapeutix earnings report?

The next expected earnings date for Ocular Therapeutix is 07 November 2024